ImmuCell soars on Q3 sales growth

ImmuCell ($ICCC) continues to chart strong sales of First Defense, its product to treat scours in calves, and investors rewarded the company for a knockout third-quarter performance. The company announced Thursday night that its total sales for the quarter grew 40% year over year to $2.47 million and that its net income came in at $351,000, or $0.11 per diluted share. For the first 9 months, the company swung from a net loss of $298,000 ($0.10 a share) to $924,000, or $0.29 per share. Strong demand for First Defense has left the company with a $1.5 million backlog, but it is making headway in its efforts to increase its production capacity, CEO Michael Brigham said in a press release. The company's stock price jumped 10% in after-hours trading to $7.45. Release

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal…